Returning to Opioid Use After Treatment: Why It Happens and How to Find Better Support
If you have returned to fentanyl, heroin, oxycodone or another opioid after treatment, it does not mean that further treatment is pointless. It means your current circumstances and medical needs deserve another careful assessment.
Some people leave rehabilitation feeling confident, only to encounter withdrawal symptoms, powerful cravings, stressful relationships, untreated mental-health concerns or familiar environments that make remaining off opioids difficult.
Others experience several treatment episodes without receiving continuing medication or sufficient follow-up support.
The important question is not simply why an earlier attempt failed. It is what should change in the treatment plan to improve safety and support ongoing recovery.
Seek an updated assessment from a qualified addiction-treatment professional. Review whether your previous care adequately addressed withdrawal, cravings, medication needs, mental health, overdose prevention and continuing support.
Methadone and buprenorphine are effective medications for opioid use disorder. Naltrexone may be appropriate for selected patients who can complete safe medical initiation.
Do not attempt to repeat an unsupported withdrawal process or abruptly stop prescribed medication. If you may have overdosed, seek emergency assistance immediately.
This guide is educational and is not a diagnosis, medical assessment or guarantee of a particular outcome.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared for clinical review. Its discussion of opioid treatment, repeated returns to use, medical transitions and long-acting naltrexone implants must be evaluated by an appropriately qualified clinician before the content is represented as medically approved.
View Dr Fergus Law’s Professional Profile
Jump to a Section
Why Do People Return to Opioid Use After Treatment?
Returning to opioid use after a period of treatment can happen for several reasons. Opioid use disorder affects physical dependence, brain reward pathways, emotional responses, behaviours and everyday life.
A person may genuinely want recovery, complete a course of treatment and still encounter difficulties that were not adequately addressed.
A return to use can indicate that treatment needs to be adjusted, intensified, resumed or made more accessible. It should prompt a careful clinical review rather than a simplistic judgment about motivation.
Common contributing factors
Persistent cravings
A patient may continue experiencing powerful urges to use opioids, particularly when exposed to stress, memories or familiar situations.
Withdrawal and physical discomfort
An incomplete or poorly supported transition may leave a person struggling with distressing symptoms or difficulty maintaining treatment.
Environmental triggers
Returning to people, places and routines associated with past opioid use may make recovery more difficult.
Insufficient continuing care
A short period of residential treatment may not include enough medication management, follow-up or practical support after discharge.
Untreated mental-health concerns
Depression, anxiety, trauma-related symptoms and other psychiatric difficulties may require coordinated assessment and treatment.
A treatment approach that did not fit
The original programme may not have matched the person’s medical needs, preferences or circumstances.
What information can a return to use provide?
A clinician can explore when opioid use resumed, what was happening at the time, whether medication was continued and which supports were available.
This information can help identify practical changes to the treatment plan.
A patient completes 30 days in a rehabilitation facility and feels motivated to remain off opioids.
After returning home, they experience disrupted sleep, anxiety and strong cravings. They have no follow-up appointment for several weeks, and their previous social environment remains unchanged.
They return to opioid use.
A useful clinical response would examine access to medication treatment, immediate follow-up, craving management, mental-health needs and support in the patient’s home environment.
Simply repeating the same programme without addressing these gaps may leave the same risks in place.
What should patients and families avoid?
Avoid assuming that a previous return to use predicts permanent failure. Also avoid assuming that another short detoxification episode, on its own, will resolve the underlying condition.
A revised plan should address both immediate safety and long-term treatment.
Back to top ↑How Withdrawal and Cravings Can Contribute to Returning to Opioid Use
Physical withdrawal and cravings are related but distinct challenges. Effective care should consider both.
Physical withdrawal
When a person is physically dependent on opioids, reducing or stopping opioid exposure can produce symptoms such as nausea, diarrhoea, restlessness, sweating, muscle pain, anxiety and insomnia.
Symptoms vary according to the substance, duration of use, other medications and individual health.
Someone who has experienced intense withdrawal may return to opioids partly to obtain relief.
Cravings
Cravings are strong urges to use a substance. They may occur during withdrawal, after withdrawal has ended or in response to emotional and environmental triggers.
Cravings can sometimes appear unexpectedly, even after a period of improvement.
Why detoxification alone may not be enough
Withdrawal management addresses an important immediate problem, but it does not automatically provide continuing protection against overdose, cravings or return to use.
The CDC advises that detoxification alone, without medication treatment for opioid use disorder, is not recommended because of increased risks of resumed use, overdose and overdose death.
What can reduce these risks?
- Appropriate evidence-based medication treatment.
- Timely follow-up after withdrawal management or discharge.
- Assessment of co-occurring mental-health conditions.
- Planning for cravings and triggers.
- Overdose education and naloxone access.
- Reliable communication with the treating team.
A person completes medically supervised withdrawal and no longer experiences the most intense physical symptoms.
However, cravings remain strong. The person begins sleeping poorly and struggles when meeting friends associated with previous drug use.
A clinician can review medication options, counselling needs and practical strategies for these situations.
Questions to ask
- Will my treatment continue after withdrawal symptoms improve?
- What medications could help reduce cravings or support recovery?
- Who should I contact if cravings become difficult to manage?
- What should I do if I return to opioid use?
- How will overdose risk be addressed?
Why Reviewing Previous Treatment Is Essential
When someone has attended more than one treatment programme, the solution is not necessarily another identical admission.
A qualified clinician should examine what was provided previously, which parts helped and what difficulties remained unresolved.
Review the medication plan
Was the patient offered methadone or buprenorphine? If medication was prescribed, did it help? Was it continued after discharge?
If medication was discontinued, why did that happen, and was the decision medically appropriate?
Review withdrawal management
Ask whether withdrawal was adequately assessed and managed. Some patients may have left treatment before symptoms stabilised or experienced significant difficulty when returning home.
Review counselling and mental-health care
Was counselling available after discharge? Did it address anxiety, depression, trauma, relationships and other relevant concerns?
Were appointments accessible, and was the patient able to engage with the proposed service?
Review environmental and financial barriers
Treatment may become difficult to sustain when a person cannot afford appointments, obtain transport, maintain housing or arrange time away from work.
These barriers should be included in the assessment rather than treated as unrelated problems.
During the first treatment episode, a patient received withdrawal management but no continuing medication or structured follow-up.
During the second episode, they received medication and counselling but could not attend appointments after moving to another city.
A revised plan might prioritise accessible medication care, remote or local counselling and clear arrangements for continuing treatment after relocation.
A useful treatment history checklist
- Dates and names of previous treatment programmes.
- Medications used during and after treatment.
- Previous withdrawal difficulties.
- Length of time treatment was continued.
- Cravings or other symptoms after discharge.
- Counselling and psychiatric services received.
- Practical barriers to ongoing appointments.
- What happened immediately before returning to use.
Patients and families can bring this information to a new clinical assessment.
Back to top ↑Why Environment, Stress and Daily Life Matter
Treatment does not occur in isolation from the rest of a person’s life.
Someone may receive effective clinical care and still face housing insecurity, financial pressure, difficult relationships, emotional triggers or regular exposure to drug use.
Recognising patterns
A useful recovery plan identifies situations associated with previous opioid use and develops realistic responses.
For example, cravings may be linked to particular times of day, places, social contacts or emotional states.
Practical changes may help
- Arrange regular contact with the treatment team.
- Identify trusted people who can provide support.
- Discuss difficult living circumstances with a clinician or social worker.
- Develop plans for high-risk situations.
- Maintain access to medication and healthcare appointments.
- Ask for help with housing, transport or financial barriers when available.
What if avoiding every trigger is impossible?
It may not be realistic to change employment, housing or social circumstances immediately.
Counselling can help someone develop coping strategies while practical support is arranged.
A patient returns to a neighbourhood where they previously obtained opioids. They cannot move immediately because of family and employment responsibilities.
Rather than treating relocation as the only solution, the care team can help develop practical strategies for avoiding known high-risk situations, maintaining treatment and obtaining support when cravings increase.
What can family members contribute?
Family members may be able to assist with appointments, transport, communication and a safer living environment.
Their involvement should respect the patient’s privacy and preferences and should not expose anyone to violence or coercion.
Back to top ↑Which Medications Are Supported by Evidence?
Methadone, buprenorphine and naltrexone are medications used in opioid use disorder treatment.
They work differently and are not interchangeable without clinical assessment.
Methadone
Methadone is a long-acting full opioid agonist. It can reduce withdrawal symptoms and cravings and is supported by extensive evidence for treating opioid use disorder.
It may be an appropriate long-term treatment for people who have returned to opioid use following other approaches.
A person who has repeatedly returned to heroin after unsupported withdrawal may benefit from a clinical assessment for methadone treatment.
Buprenorphine
Buprenorphine is a partial opioid agonist that can reduce withdrawal symptoms and cravings.
It can be continued as an effective long-term treatment, and clinical initiation strategies should account for recent opioid exposure and individual medical circumstances.
Someone who returned to fentanyl use after residential treatment may discuss buprenorphine with an addiction clinician, including how initiation and ongoing follow-up would be managed.
Naltrexone
Naltrexone is an opioid antagonist. It blocks opioid receptor activity and may be considered for selected patients who prefer an antagonist-based approach.
However, naltrexone can cause severe precipitated withdrawal when administered too early after opioid use.
Appropriate initiation requires professional assessment and monitoring.
Is one approach automatically better?
No. The most appropriate treatment depends on medical history, prior treatment outcomes, ongoing risk, patient preferences and practical access to care.
Methadone and buprenorphine have especially strong evidence for reducing overdose-related mortality. Naltrexone may be suitable for selected patients who can complete safe induction and remain engaged in treatment.
A person considering a move from methadone or buprenorphine to naltrexone should discuss the risks and alternatives with a qualified clinician.
An advertised rapid transition does not mean that the process is safe or suitable for everyone.
Overdose Prevention After Treatment: Why It Matters
Overdose prevention is particularly important when someone has resumed opioid use after a period of abstinence or reduced use.
Opioid tolerance may decrease during a period without opioids. If a person later takes an amount similar to what they previously used, the risk of overdose may be greater.
What else can increase overdose risk?
- Unknown fentanyl or other potent opioids in unregulated drugs.
- Using opioids together with benzodiazepines or alcohol.
- Reduced tolerance following abstinence or treatment.
- Using alone without someone available to respond.
- Interrupted medication treatment or loss of clinical support.
- Trying to overcome opioid antagonist blockade.
How can naloxone help?
Naloxone is a medication that can reverse an opioid overdose when administered in time.
Patients, family members and trusted supporters should know how to obtain naloxone, recognise possible overdose and contact emergency services.
Possible overdose signs
- Very slow or absent breathing.
- Inability to wake the person.
- Gurgling or choking sounds.
- Blue, grey or unusually pale lips or skin.
- Loss of responsiveness.
Emergency actions
- Call emergency services immediately.
- Administer naloxone if available.
- Follow emergency dispatcher guidance.
- Support breathing as directed.
- Remain with the person until help arrives.
Does a naltrexone implant eliminate overdose risk?
No. A naltrexone implant should never be described as guaranteeing protection against overdose.
Attempting to overcome opioid blockade with large doses can be fatal.
Risk may also increase when the antagonist effect diminishes and tolerance has declined.
If an opioid overdose is suspected, call emergency services immediately and administer naloxone if available.
Even if the person responds, they still require medical assessment because opioid effects can recur after naloxone wears off.
What If a Treatment Centre Refuses Admission After Previous Relapses?
Some programmes may be unable to meet a patient’s needs because of medical complexity, staffing, available services or other admission requirements.
However, repeated returns to opioid use should not automatically be interpreted as proof that someone cannot benefit from treatment.
Ask for the actual reason
A facility might be concerned about medical instability, psychiatric needs, medication requirements or the need for a different level of care.
An explanation helps identify what type of provider may be appropriate.
What should you ask?
- Is this a clinical or administrative decision?
- What specific admission requirement has not been met?
- Was my case individually reviewed?
- Would a different level of care be more appropriate?
- Can you provide a referral?
- What support is available while I seek another service?
A person has attended rehabilitation three times. A fourth facility declines admission because it believes the patient needs more intensive medical management.
Instead of viewing the refusal as the end of treatment, the patient can request clarification and assessment by a service able to provide the recommended level of care.
What if the refusal feels unfair?
Request the provider’s admission criteria in writing. Depending on the circumstances, patient advocacy or legal guidance may help clarify whether the decision is consistent with applicable requirements.
The immediate priority remains access to appropriate treatment and maintaining safety.
Back to top ↑Mental Health, Trauma and Family Support After Returning to Use
Mental-health symptoms, social stress and family relationships may influence recovery.
A person who has returned to opioid use may be experiencing shame, fear, anxiety or distress about disappointing loved ones.
These feelings can make it harder to seek care again.
Why mental-health assessment matters
Depression, anxiety, trauma-related symptoms and other psychiatric difficulties may require specialist treatment alongside addiction care.
Patients should explain any concerning symptoms to a qualified clinician.
How should family members respond?
Family involvement can be constructive when it is respectful, voluntary and focused on practical support.
Useful actions include helping arrange an appointment, providing transport, understanding overdose response and encouraging continuing treatment.
What should family members avoid?
- Demanding that a person stop prescribed medication without medical advice.
- Assuming that another treatment episode is pointless.
- Using threats or humiliation as a substitute for care.
- Ignoring overdose risk after a period of abstinence.
- Making treatment decisions without the patient’s informed participation.
A family member might say:
“I am concerned about your safety and want to help you find care that addresses what happened after your previous treatment. Would you like help arranging an appointment or speaking with your current clinician?”
This approach focuses on support and practical action rather than blame.
When urgent specialist help is necessary
Acute suicidal danger, serious psychiatric instability, overdose and other medical emergencies require immediate appropriate local care.
A planned overseas programme cannot replace urgent assessment or emergency treatment.
Back to top ↑Could DeBinge in The Bahamas Be an Option?
DeBinge describes a physician-supervised treatment pathway in Sandyport, Nassau, for selected adults considering naltrexone-based opioid recovery.
The programme includes assessment for a supervised opioid transition, possible long-acting naltrexone implantation and ongoing counselling.
It may be of interest to some people who have returned to opioid use after previous treatment and wish to discuss an antagonist-based approach.
What is different about the described transition?
DeBinge describes a supervised pathway involving buprenorphine rather than requiring eligible patients to complete a separate opioid-free waiting period before arriving for treatment.
However, the patient must still be assessed for safe naltrexone initiation. Administering naltrexone too early can cause severe precipitated withdrawal.
Individual treatment timing cannot be guaranteed.
How does the implant work?
Naltrexone is an opioid antagonist. While clinically effective medication levels are present, it can block opioid receptor effects.
The implanted formulation used by DeBinge is not FDA-approved in the United States and is distinct from FDA-approved extended-release injectable naltrexone.
Will implantation guarantee recovery?
No. The implant cannot guarantee that a person will never return to opioid use, experience cravings or overdose.
Medication is one component of a broader treatment approach, and continued monitoring and support remain important.
What should someone with previous relapses ask?
- How would my previous treatment history affect eligibility?
- What options are available if I am currently using fentanyl?
- What if I am taking methadone or buprenorphine?
- How are withdrawal symptoms assessed and managed?
- What evidence supports this particular implant?
- What risks should I understand before consenting?
- What happens if the clinical team decides not to proceed?
- What aftercare is provided following my return home?
DeBinge cannot be assumed appropriate for every person who has returned to opioid use.
Methadone and buprenorphine remain established evidence-based alternatives and may offer greater clinical benefit or safety for some patients.
Do not stop prescribed medication or attempt your own transition before receiving individual guidance.
Why Counselling and Continuing Care Matter After Initial Treatment
One of the most important questions for someone who has returned to opioid use after previous treatment is what support will be available after the next treatment episode.
Recovery planning should not end at discharge.
What can counselling help address?
Recognising cravings
Identifying situations and emotional responses associated with previous opioid use.
Managing stress
Developing strategies for challenging circumstances that may otherwise lead to substance use.
Relationships
Improving communication, boundaries and access to supportive people where appropriate.
Continuing recovery goals
Maintaining appointments, addressing practical barriers and reviewing progress over time.
What does DeBinge advertise?
DeBinge describes a programme that includes one year of counselling.
Patients should confirm the current frequency of sessions, whether they are remote, who provides them and how missed appointments and urgent concerns are handled.
What about medical follow-up?
Counselling does not replace medical care. Patients should also understand who will assess implant-related concerns, co-occurring conditions, pain treatment needs and any continuing medication requirements.
Example: Preparing for the return home
Before leaving the treatment setting, a patient arranges their first counselling appointment, identifies a local clinician, obtains naloxone information and prepares a plan for situations associated with previous opioid use.
If difficulties arise, the patient has specific contacts and next steps rather than being left to work out a new plan alone.
- When is my first follow-up appointment?
- Who will provide medical advice after I return home?
- What should I do if cravings increase?
- How can family members participate if I want their support?
- What happens if I return to opioid use?
- What emergency arrangements should I understand?
Financial Planning, Travel and Practical Requirements
If considering treatment abroad, patients should understand the complete medical and financial arrangements before booking travel or paying a deposit.
Request a written quote
A previously discussed DeBinge package figure of approximately $22,000 should be confirmed directly. Do not assume this remains the current fee or includes every possible expense.
Medical costs to clarify
- Initial assessment and testing.
- Medical supervision.
- Medication and transition care.
- Naltrexone implantation.
- Additional treatment or complications.
- Follow-up and counselling.
Additional costs to clarify
- Flights and transfers.
- Accommodation.
- Travel changes or delays.
- Extended medical stays.
- Emergency hospital treatment.
- Healthcare after returning home.
Does insurance cover overseas treatment?
Coverage depends on the insurer, the plan and the specific treatment.
Patients should not assume that an overseas naltrexone implant will be covered, especially when the formulation is not FDA-approved in the United States.
Request written confirmation of any coverage, exclusions, pre-authorisation requirements and reimbursement terms.
What happens if implantation cannot proceed?
Ask for written information about medical reassessment, alternative care, postponed treatment, cancellation terms and potential refunds.
Clinical eligibility should never be assumed simply because travel has been arranged or a payment has been made.
“Please confirm the current total programme price and everything included. What additional medical or accommodation expenses could arise?”
“What happens if my medical assessment shows that implantation is not suitable or must be delayed?”
“How will follow-up be provided when I return to the United States?”
Twenty Questions Patients and Families Should Ask
1. Why might someone who has returned to use struggle to get treatment?
Some services lack the medical or psychiatric resources required for complex circumstances. Others may have restrictive medication policies, limited capacity or specific admission criteria.
Repeated returns to opioid use should lead to reassessment of medical needs, not an assumption that the person is unable to benefit from treatment.
Ask the provider whether the refusal relates to clinical suitability, programme capability or an administrative requirement, and request an appropriate referral.
2. Does this mean every clinic will turn them away?
No. Addiction services operate at different levels of care. A centre unable to provide suitable treatment may refer someone to a hospital-based service, opioid treatment programme, outpatient prescriber or another specialist provider.
The priority is finding a service that can assess and address the actual clinical needs.
3. Is this discrimination or a clinical capability issue?
The answer depends on the circumstances. Some refusals reflect genuine limitations in staffing or facilities. Other exclusions may raise concerns if they are based on unsupported assumptions or inconsistent treatment policies.
Request written reasons and ask whether an individual clinical review is available. Appropriate patient advocacy or legal advice may help where discrimination is suspected.
4. What should someone ask a clinic before applying?
Ask whether the programme treats people with previous treatment episodes, offers evidence-based medication, manages complex withdrawal and provides follow-up after discharge.
Confirm whether psychiatric services, emergency arrangements and coordination with existing prescribers are available.
“I have previously completed addiction treatment but returned to opioid use. I would like an individual assessment of what was missing from my previous care. Can your programme review my medication options and create a continuing treatment plan?”
5. What should happen during the first medical assessment?
The clinician should review current substances and medications, previous treatments, physical and mental health, withdrawal experiences and immediate safety.
They should also ask what happened after prior treatment, including cravings, access to medication, follow-up and social circumstances.
This information helps determine what changes may be needed.
6. Which treatments are supported by evidence?
Methadone and buprenorphine are strongly supported treatments for opioid use disorder and are associated with reduced overdose-related harms.
Naltrexone may be suitable for selected people after safe initiation. Medication choices should be discussed with a qualified clinician and considered alongside ongoing psychosocial support.
7. Does everyone need to stop opioids before getting help?
No. People can seek assessment and begin appropriate care while physically dependent on opioids.
Methadone and buprenorphine do not require completion of detoxification before treatment.
Naltrexone has different requirements because administering it too early can cause precipitated withdrawal.
8. Can methadone or buprenorphine remain appropriate?
Yes. These medications can be appropriate as long-term treatment and may help patients maintain stability.
Returning to opioid use does not automatically mean they should be discontinued. A clinician may need to review adherence, access, current treatment and other factors.
9. When might naltrexone be considered?
An antagonist-based approach may be considered when a patient understands the alternatives, prefers that type of treatment and can safely complete the necessary initiation process.
It may be less suitable for someone who cannot safely transition or whose clinical needs favour continued agonist medication.
10. Why does medication history matter?
Recent fentanyl, heroin, methadone, buprenorphine or prescription opioid exposure can affect withdrawal risk and treatment planning.
Other medications and substances may also influence safety. An accurate history allows the clinician to consider interactions, dependence and possible complications.
11. Can withdrawal be managed without unnecessary suffering?
Medical treatment can help manage withdrawal symptoms and reduce distress, although symptoms cannot always be eliminated.
Methadone and buprenorphine are important options for many patients. Any transition to naltrexone requires careful assessment and monitoring.
No clinic should guarantee painless withdrawal.
12. What can a private doctor contribute?
A physician can review previous treatment, assess current medical needs, explain alternatives and supervise treatment decisions.
A private setting may allow individual attention, but patients should confirm the doctor’s credentials, availability and emergency responsibilities.
13. What can dedicated nursing support contribute?
Qualified nursing professionals can monitor symptoms, recognise changes in a patient’s condition and provide care within their professional scope.
Ask whether nursing coverage is continuous, how the physician is contacted and what happens if complications occur.
14. Does privacy improve the experience?
Privacy may support open communication and help patients feel more comfortable discussing sensitive issues.
However, privacy is not a substitute for effective medication, appropriate monitoring, clinical expertise or emergency care.
15. What mental-health support might be needed?
Anxiety, depression, trauma-related difficulties and other psychiatric concerns may require assessment and treatment.
Care should address these needs alongside opioid use disorder. Someone with an acute psychiatric emergency or serious medical instability may require immediate local specialist care.
16. How should family or other responsibilities be planned for?
Arrange practical matters such as childcare, transport, employment responsibilities and communication before beginning treatment.
Family members may be able to help with appointments, daily support and overdose education, provided the involvement is safe and welcomed by the patient.
17. What are the risks of travelling for treatment?
International treatment may involve travel delays, unexpected costs, difficulties accessing emergency care and challenges coordinating follow-up after returning home.
Clinical screening should determine whether the patient is suitable for travel and the proposed programme.
18. What should a patient ask about the price?
Request the total price in writing, including medical assessment, medications, procedure, accommodation and counselling.
Clarify additional expenses, cancellation terms, possible emergency charges and what happens if treatment must be delayed or changed.
19. What happens after the initial stay?
Continuing care may involve medication management, counselling, medical follow-up, mental-health treatment and support for the patient’s home circumstances.
Before discharge, confirm appointments, relevant clinical contacts and what to do if cravings, side effects or opioid use recur.
20. What is the safest next step today?
Contact an appropriately licensed local addiction-treatment professional for assessment.
If previous treatment was followed by a return to opioid use, explain what happened and request a review of medication options, overdose prevention and continuing support.
If considering DeBinge, request a confidential eligibility discussion and provide an accurate medical history. Do not stop prescribed medication in preparation for travel.
Neither residential treatment nor a naltrexone implant guarantees that relapse or overdose will never occur.
The most appropriate care is based on individual clinical assessment, evidence-based treatment, realistic risk management and continuing support.
Four Steps After Returning to Opioid Use
Assess urgent risks, seek medical help when needed and make sure naloxone is available.
Identify what helped, what did not and what happened after treatment ended.
Discuss medication, clinical needs, counselling and suitable treatment settings.
Arrange follow-up, family or peer support and an individual overdose response plan.
Step 1: Address current safety
If overdose is suspected, contact emergency services immediately and administer naloxone if available.
For non-emergency concerns, contact a qualified healthcare provider promptly to discuss current substance use, medication and treatment needs.
Step 2: Identify what happened after previous treatment
Write down the timeline of previous treatment, medication changes, cravings, appointments and significant events before opioid use resumed.
Step 3: Ask for a revised clinical plan
Discuss whether methadone, buprenorphine, naltrexone or other appropriate support may be suitable.
The revised plan should reflect the patient’s medical needs and choices rather than automatically repeating an earlier approach.
Step 4: Arrange support beyond discharge
Before entering treatment, identify where follow-up will take place, who will provide medical advice and what to do if new difficulties emerge.
Contact a qualified local treatment provider, explain the return to opioid use, review current prescriptions and previous treatment, ask about appropriate medication and arrange timely follow-up.
Ask about naloxone availability and emergency warning signs. Urgent medical problems should not wait for a routine appointment.
20-Question Recovery Planning Self-Check
This checklist is designed for people who have returned to opioid use after previous treatment and want to prepare for a new clinical discussion.
Answer each question to identify areas where you may need more information, treatment support or a practical plan.
This questionnaire does not diagnose opioid use disorder, evaluate overdose risk, determine medical suitability or recommend a particular treatment.
Additional Questions About Returning to Opioid Use
Does returning to opioid use mean treatment has permanently failed?
No. A return to use can indicate that the treatment plan needs reassessment or additional support.
A qualified clinician should review medication, cravings, withdrawal, other health concerns and circumstances surrounding the return to use.
Should someone repeat the same detoxification programme?
Not automatically. A clinician should examine why the previous programme was followed by a return to opioid use and whether changes to ongoing medication, follow-up or other support are needed.
Withdrawal management alone is not recommended as the sole treatment for opioid use disorder.
Can methadone help someone who has repeatedly returned to heroin or fentanyl?
Methadone is an established treatment that can reduce withdrawal symptoms, cravings and illicit opioid use.
A qualified clinician can assess whether it is appropriate for the individual’s circumstances.
Can buprenorphine be used after previous unsuccessful treatment?
Yes. Previous treatment difficulties do not automatically exclude someone from buprenorphine treatment.
A clinician can review appropriate initiation, ongoing care and factors affecting treatment engagement.
Does naltrexone stop every craving?
No. Naltrexone can help some people reduce cravings and block opioid effects, but psychological and environmental triggers may remain.
Continuing treatment and counselling may still be necessary.
Does a naltrexone implant guarantee that overdose cannot occur?
No. Attempting to overcome opioid blockade can be fatal, and overdose risk may increase after blockade diminishes or tolerance declines.
Patients require overdose education and a practical emergency plan.
Is the DeBinge naltrexone implant approved in the United States?
No. The long-acting implant described by DeBinge is not FDA-approved in the United States.
It is distinct from FDA-approved extended-release injectable naltrexone.
What if I am still taking methadone or buprenorphine?
Do not stop prescribed medication in preparation for another programme without consulting your prescriber.
Continuing agonist treatment may remain the safest and most effective approach for some individuals.
How can family members help after a return to use?
Family members can offer practical support, help with appointments, learn overdose response, encourage appropriate treatment and participate in counselling where suitable.
Respectful communication and the patient’s informed participation are important.
Where can someone find treatment if a clinic refuses admission?
In the United States, FindTreatment.gov can help locate addiction treatment services.
An existing clinician, local health service or addiction specialist can also help arrange an appropriate referral.
Clinical Sources and Helpful Resources
CDC: Treating Opioid Use Disorder
Guidance about evidence-based medications, overdose prevention and why detoxification alone is not recommended.
Read CDC guidanceSAMHSA: Medications for Opioid Use Disorder
Information about methadone, buprenorphine, naltrexone and continuing treatment.
Read SAMHSA guidanceNIDA: Opioids and Treatment
Research into opioid use disorder, medication treatment and overdose-related harms.
Explore NIDA resourcesASAM Clinical Guidance
Clinical recommendations about addiction treatment and medication decisions.
Visit ASAMCDC: Naloxone and Overdose Response
Information about recognising and responding to opioid overdose.
Read overdose guidanceA Return to Opioid Use Should Lead to Better Planning, Not Less Support
If you have experienced repeated returns to opioid use and want to understand whether a different medical approach may be appropriate, request a confidential discussion with DeBinge.
The clinic can explain its assessment process, supervised transition programme, possible naltrexone treatment, private medical care and counselling arrangements.
Suitability depends on individual assessment, and methadone or buprenorphine may remain more appropriate for some patients.
Before making a decision, ask about risks, alternatives, treatment costs, medical monitoring and follow-up.
Request a Confidential Suitability Consultation
Do not stop or change prescribed medication in preparation for treatment without medical guidance.
Medical disclaimer: This article provides general educational information and is not individual medical advice. Treatment for opioid use disorder should be guided by qualified professionals. DeBinge’s long-acting naltrexone implant is not FDA-approved in the United States. The implant does not guarantee the prevention of relapse or overdose. Programme details, clinical eligibility, costs and follow-up must be confirmed directly. Clinical review approved by Dr Fergus Law on 15 October 2026.